NO20072705L - Alfa-tymosinpeptider som cancervaksineadjuvanser - Google Patents

Alfa-tymosinpeptider som cancervaksineadjuvanser

Info

Publication number
NO20072705L
NO20072705L NO20072705A NO20072705A NO20072705L NO 20072705 L NO20072705 L NO 20072705L NO 20072705 A NO20072705 A NO 20072705A NO 20072705 A NO20072705 A NO 20072705A NO 20072705 L NO20072705 L NO 20072705L
Authority
NO
Norway
Prior art keywords
cancer vaccine
alpha
subject
vaccine adjuvants
thymosin peptides
Prior art date
Application number
NO20072705A
Other languages
English (en)
Norwegian (no)
Inventor
Alfred R Rudolph
Gustavo Antonio Moviglia
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20072705L publication Critical patent/NO20072705L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20072705A 2004-12-06 2007-05-29 Alfa-tymosinpeptider som cancervaksineadjuvanser NO20072705L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (1)

Publication Number Publication Date
NO20072705L true NO20072705L (no) 2007-09-05

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072705A NO20072705L (no) 2004-12-06 2007-05-29 Alfa-tymosinpeptider som cancervaksineadjuvanser

Country Status (15)

Country Link
US (1) US20100092499A1 (https=)
EP (1) EP1835931A4 (https=)
JP (1) JP2008523067A (https=)
KR (1) KR20070086663A (https=)
CN (1) CN101072582B (https=)
AU (1) AU2005314271B2 (https=)
BR (1) BRPI0518571A2 (https=)
CA (1) CA2588685A1 (https=)
EA (1) EA015510B1 (https=)
IL (1) IL183264A (https=)
MX (1) MX2007006717A (https=)
NO (1) NO20072705L (https=)
NZ (1) NZ555571A (https=)
UA (1) UA90493C2 (https=)
WO (1) WO2006062917A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
JP6385280B2 (ja) * 2012-01-20 2018-09-05 トーメ クロイツ、フェルナンド 自家癌細胞ワクチン
JP2015510887A (ja) * 2012-03-08 2015-04-13 サイクローン・ファーマシューティカルズ・インコーポレイテッドＳｃｉＣｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 化膿性鼻副鼻腔炎の処置のためのチモシンαの使用
EP3943101A1 (en) * 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
MXPA02000192A (es) * 1999-06-30 2004-08-12 Corixa Corp Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
ES2299626T3 (es) * 2001-10-26 2008-06-01 Rhode Island Hospital Aumento de timosina para asegurar una inmunizacion genetica.
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
JP2005537246A (ja) 2002-06-28 2005-12-08 サイクローン・ファーマシューティカルズ・インコーポレイテッド サイマルファシンを用いて腫瘍抗原発現をアップレギュレートする方法
EA008037B1 (ru) * 2003-03-28 2007-02-27 Сциклон Фармасьютикалс, Инк. ЛЕЧЕНИЕ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ГРИБАМИ p. ASPERGILLUS, С ПОМОЩЬЮ ТИМОЗИНА АЛЬФА 1
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Also Published As

Publication number Publication date
CA2588685A1 (en) 2006-06-15
EP1835931A4 (en) 2008-12-17
AU2005314271B2 (en) 2011-06-16
MX2007006717A (es) 2007-08-06
NZ555571A (en) 2009-02-28
EA200701166A1 (ru) 2008-02-28
JP2008523067A (ja) 2008-07-03
EP1835931A2 (en) 2007-09-26
AU2005314271A1 (en) 2006-06-15
BRPI0518571A2 (pt) 2008-11-25
KR20070086663A (ko) 2007-08-27
CN101072582A (zh) 2007-11-14
IL183264A (en) 2010-12-30
IL183264A0 (en) 2007-09-20
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
UA90493C2 (ru) 2010-05-11
CN101072582B (zh) 2012-06-27
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
MX2009009342A (es) Metodo novedoso y composiciones.
UA94900C2 (uk) Вакцина
NZ534919A (en) Bioactive keratin peptides
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
PL1879612T3 (pl) Zastosowanie peptydów natywnych i ich zoptymalizowanych pochodnych do szczepienia
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2011038397A3 (en) Peptide adjuvants, vaccines, and methods of use
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
SG162791A1 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
AR114683A1 (es) Polipéptidos inmunomoduladores e inmunoestimulantes para suministro de drogas
WO2003093298A3 (en) Immunogenic peptides
WO2012015979A3 (en) Hmgb1-derived peptides enhance immune response to antigens
NZ593200A (en) Peptide adjuvants
DE602005024161D1 (de) Peptid mit antitumoraler wirkung
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application